Luxin Venture Capital (600783.SS) traded flat 0 % during a 24 hours period ending at 03:21 PM Central Europe on Monday 26th. One Luxin Venture Capital stock can currently be bought for about CNY 13.26 on popular exchanges. Current supply of Luxin Venture Capital stocks is 744.2 mn. Luxin Venture Capital has a current market capitalization of CNY 9.9 bn and approximately CNY 165.7 mn worth of Luxin Venture Capital was traded on exchanges in the last 24 hours. Since last month end, Luxin Venture Capital has traded -12.88 % down. Simple moving average of last 200 days is at CNY 17.39. The highest price of past 52 weeks was recorded at CNY 39.44 on 01/13/2026. 52 weeks low was at CNY 12.33 on 10/23/2026.
Here is how related stocks have performed in the past 24 hours:
China National Accord Medi (000028.SZ) traded flat 0 % and now trades at CNY 21.06. Current market capitalisation for China National Accord Medi is CNY 11.8 bn. China National Accord Medi has a current price to earnings ratio of 11.75.
Kuaijishan Shaoxing Wine C (601579.SS) traded flat 0 % and now trades at CNY 24.02. Current market capitalisation for Kuaijishan Shaoxing Wine C is CNY 11.8 bn. Kuaijishan Shaoxing Wine C has a current price to earnings ratio of 42.31. The week’s performance for the Chinese liquor sector remained mixed. The Wind Baijiu Index fell slightly, ending the week on a modest decline after a period of rising. Among the larger brands, several maintained gains, while smaller, previously highly volatile names experienced sharper pullbacks. Analysts noted that the industry is shifting from an earlier phase of supply excess to a more balanced supply‑demand dynamic, with consumer sentiment and purchasing power still recovering. Structural segmentation—by brand, price range, and target customer—is expected to shape future opportunities. Upcoming third‑quarter earnings will likely be a focal point for investors, as many companies anticipate inventory adjustments and a potential turnaround in sales. The broader alcohol market, including yellow wine and beer, also saw notable price corrections this week.
Qingdao Baheal Pharmaceuti (301015.SZ) traded flat 0 % and now trades at CNY 25.01. Current market capitalisation for Qingdao Baheal Pharmaceuti is CNY 11.9 bn. Current price/earnings ratio for Qingdao Baheal Pharmaceuti is 24.11. On October 26, 2026, Qingdao Baoyang Pharmaceutical (now announcing a name change to Baoyang Pharmaceutical Group) saw its shares rise by more than ten percent, reflecting investor optimism about a strategic shift from a distribution model to a full‑cycle pharmaceutical enterprise. The company’s announcement highlighted the acquisition of Shanghai Baoyang Pharmaceutical, the development of high‑end manufacturing capabilities, and the integration of a diversified pipeline covering oncology, cardiovascular, and rare disease areas. Market sentiment toward the broader pharmaceutical sector remained buoyant, with several other drug‑development and biotech names also posting gains, while the overall market experienced moderate volatility. The company’s rebranding signals a move toward stronger intellectual‑property assets and a more vertically integrated business structure.
Guobang Pharma (605507.SS) traded flat 0 % and now trades at CNY 15.17. Guobang Pharma has a market capitalisation of CNY 11.9 bn. Guobang Pharma has a current price to earnings ratio of 16.69. Guobang Pharma Ltd. has reported a decline in its third‑quarter earnings, reflecting broader industry pressures. The company’s net profit fell compared with the previous year, a trend that aligns with similar reductions seen among peers in the pharmaceutical and medical device sectors. The drop is attributed to increased costs and a competitive market environment, rather than to a specific product or regulatory issue. Guobang remains focused on maintaining its research pipeline and supply chain stability while navigating the current economic backdrop.
Huabao (300741.SZ) traded flat 0 % and now trades at CNY 18.88. Huabao has a market capitalisation of CNY 11.9 bn. Current price/earnings ratio for Huabao is 60.91.
About Luxin Venture Capital
The Luxin Venture Capital Group Co., Ltd. is a materials company headquartered in Jinan, China. The company specializes in manufacturing abrasive products such as sandpaper, grinding wheels, emery cloth, and other products. Additionally, Luxin Venture Capital Group provides investment services. Their website is www.600783.cn and they are listed on the Shanghai Stock Exchange. Their IPO date is November 30th, 1988.